TABLE 1.
Baseline characteristics of participants.
| G1: No clinical pregnancy | G2: Clinical pregnancy | G3: Live birth | P-value | |
| N | 1,427 | 204 | 1,381 | |
| Age (years) | 35.33 ± 4.51 | 35.26 ± 4.10 | 34.43 ± 4.13 | <0.001 |
| BMI (kg/m2) | 21.98 ± 3.18 | 22.40 ± 3.32 | 22.16 ± 3.11 | 0.102 |
| Gravidity | 1.15 ± 1.57 | 1.04 ± 1.32 | 0.86 ± 1.26 | <0.001 |
| Parity | 0.11 ± 0.34 | 0.11 ± 0.32 | 0.07 ± 0.26 | <0.001 |
| Duration of infertility (years) | 4.82 ± 3.26 | 5.05 ± 3.43 | 4.56 ± 2.79 | 0.025 |
| Types of infertility | 0.146 | |||
| Primary infertility | 804 (56.35%) | 108 (53.20%) | 817 (59.16%) | |
| Secondary infertility | 623 (43.65%) | 96 (46.80%) | 564 (40.84%) | |
| Method | 0.389 | |||
| IVF | 990 (69.45%) | 151 (74.02%) | 960 (69.44%) | |
| ICSI | 437 (30.55%) | 53 (25.98%) | 421 (30.56%) | |
| Basal FSH (IU/L) | 8.18 ± 4.03 | 7.74 ± 3.08 | 7.60 ± 3.33 | <0.001 |
| Basal LH (IU/L) | 4.40 ± 3.55 | 4.12 ± 2.11 | 4.21 ± 2.67 | 0.166 |
| Basal PRL (ng/ml) | 17.92 ± 9.50 | 18.63 ± 10.19 | 17.82 ± 8.62 | 0.503 |
| Basal E2 (pg/ml) | 50.66 ± 31.17 | 49.93 ± 25.82 | 51.55 ± 34.40 | 0.675 |
| Basal T (ng/ml) | 0.48 ± 0.78 | 0.56 ± 1.49 | 0.45 ± 0.43 | 0.104 |
| Total consumption of r-FSH (dose) | 36.11 ± 12.60 | 32.72 ± 9.84 | 30.16 ± 16.11 | <0.001 |
| Total consumption of HMG (dose) | 5.19 ± 3.71 | 5.08 ± 3.89 | 4.95 ± 4.05 | 0.002 |
| COH protocol | 0.009 | |||
| GnRH-a long protocol | 896 (62.79%) | 127 (62.25%) | 960 (69.51%) | |
| GnRH-a ultra-long protocol | 30 (2.10%) | 7(3.43%) | 37 (2.68%) | |
| GnRH-a short protocol | 2 (0.01%) | 0 (0.00%) | 2 (0.14%) | |
| GnRH-ant protocol | 496 (34.76%) | 70 (34.31%) | 382 (27.66%) | |
| Mini-stimulation protocol | 3 (0.21%) | 0 (0.00%) | 0 (0.00%) |
BMI, body mass index; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; FSH, follicle-stimulating hormone; E2, estrogen; LH, luteinizing hormone; PRL, prolactin; T, testosterone; GnRH-a, gonadotropin-releasing hormone agonist; GnRH-ant, gonadotropin-releasing hormone antagonist; COH, controlled ovarian hyperstimulation; r-FSH, recombinant FSH; HMG, human menopausal gonadotrophin.